EUVIMEDDescoperă EUVIMED
Crossref

Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel

Thomas J Galletta iD, Jeremy D Rubinstein iD, Christa Krupski, Adam S Nelson, Ruby Khoury, Christopher E Dandoy iD, Stella M Davies iD, Christine L Phillips

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30271 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2023. Written by Thomas J Galletta and 7 co-authors. Institution: Cincinnati Children's Hospital Medical Center Cancer and Blood Diseases Institute, Cincinnati, Ohio, USA. Major MEDLINE topics: Receptors, Chimeric Antigen, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Cited 7 times so far (Crossref); 28 references.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

CD19‐directed chimeric antigen receptor T lymphocytes (CAR‐T) have led to durable remissions in children with refractory and/or multiply relapsed B‐lymphoblastic leukemia. For those who relapse or lose B‐cell aplasia post CAR‐T, the role of CAR‐T reinfusion is unclear. We report two cases of durable remission with tisagenlecleucel reinfusion despite failure to achieve or maintain B‐cell aplasia, and compare these cases to six additional children who received multiple tisagenlecleucel infusions at our institution. Our experience suggests that reinfusion is safe and may be a definitive therapy for a small subset of patients. Reinfusion can also reintroduce remission and/or B‐cell aplasia, allowing for subsequent therapies.

Subjects

MeSH terms (MEDLINE)

Receptors, Chimeric AntigenPrecursor Cell Lymphoblastic Leukemia-LymphomaChildHumansReceptors, Antigen, T-CellRemission InductionAntigens, CD19Adaptor Proteins, Signal TransducingImmunotherapy, Adoptive

Author keywords

B-cell aplasiaB-lymphoblastic leukemiaCAR-TCTL019reinfusiontisagenlecleucel

Substances

tisagenlecleucelReceptors, Chimeric AntigenReceptors, Antigen, T-CellAntigens, CD19Adaptor Proteins, Signal Transducing

Authors and institutions

  • Cincinnati Children's Hospital Medical Center Cancer and Blood Diseases Institute, Cincinnati, Ohio, USA.
  • Cincinnati Children's Hospital Medical Center Division of Oncology, Cincinnati, Ohio, USA.
  • University of Cincinnati College of Medicine Department of Pediatrics, Cincinnati, Ohio, USA.
  • Cincinnati Children's Hospital Medical Center Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, Ohio, USA.

ORCID profiles: Thomas J Galletta, Jeremy D Rubinstein, Christopher E Dandoy, Stella M Davies

Cite

APA

Galletta, T. J., Rubinstein, J. D., Krupski, C., Nelson, A. S., Khoury, R., Dandoy, C. E., Davies, S. M., & Phillips, C. L. (2023). Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30271

Vancouver

Galletta TJ, Rubinstein JD, Krupski C, Nelson AS, Khoury R, Dandoy CE, et al. Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30271

BibTeX
@article{Galletta2023,
  author = {Galletta, Thomas J and Rubinstein, Jeremy D and Krupski, Christa and Nelson, Adam S and Khoury, Ruby and Dandoy, Christopher E and Davies, Stella M and Phillips, Christine L},
  title = {Durable remissions achieved with reinfusion of CD19‐directed CAR‐T despite failure to induce or maintain B‐cell aplasia and single‐center experience with reinfusion of tisagenlecleucel},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30271}
}
Start for free →